Efficacy and Safety of Netakimab in Children and Adolescents with Moderate-to-Severe Plaque Psoriasis: Results of the Core Treatment Period (12 Weeks) of the Randomized Placebo-Controlled Phase III Clinical Trial BCD-085-16/PLANETA-KIDS
Current Pediatrics · 21.07.2026 · 25 (3) · 173-188
DOI: 10.15690/vsp.v25i3.3056 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Pediatrics, online erschienen am 21.07.2026. Verfasst von Nikolay N. Murashkin und 20 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Netakimab is a humanized anti-interleukin-17A monoclonal antibody, it has marketing approval for treatment of adult patients with moderate-tosevere plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. This paper provides the results of the first 12-week period of phase III BCD-085-16/PLANETA-KIDS clinical study.
Objective
The aim of the BCD-085-16/PLANETA-KIDS is to evaluate netakimab efficacy and safety in pediatric patients 6+ years old with moderate-to-severe plaque psoriasis.
Methods
BCD-085-16/PLANETA-KIDS (NCT06640517) is a randomized, double-blind, placebo-controlled phase III clinical study with open-label active-comparator arm (adalimumab). A total of 155 male and female patients aged from 6 to 18 years with confirmed moderate-to-severe plaque psoriasis were randomized to receive netakimab (n = 83), placebo (n = 35), or adalimumab (n = 37). Netakimab dosage was weight adjusted: for patients weighing 50 kg or more netakimab dose was 120 mg (two injections of 60 mg/ml each), for patients weighing less than 50 kg netakimab dose was 60 mg (one injection of 60 mg/ml). Patients in the Netakimab group received netakimab subcutaneously once per week for the first three weeks (induction) and once every 4 weeks thereafter (maintenance). Patients in the Placebo group received placebo in blinded manner like netakimab. Adalimumab was administered in open-label way in doses recommended by the product’s SmPC. In this study co-primary efficacy endpoints were the proportion of patients achieving PASI75 and sPGA0/1 at week 12.
Results
Netakimab has shown superiority over placebo for both co-primary endpoints. The proportion of patients achieving PASI75 at week 12 was 89.2% in the Netakimab group and 14.3% in the Placebo group, odds ratio (OR) 59.0, 95% CI [16.5; 211.5] (p < 0.0001). The proportion of patients achieving sPGA0/1 at week 12 was 83.1% in the Netakimab group and 8.6% in the Placebo group, OR 54.9, 95% CI [14.6; 206.5] (p < 0.0001). The subgroup analysis has shown consistent netakimab superiority over placebo for both co-primary endpoints, regardless of age, body weight and psoriasis severity. Throughout the 12-week period netakimab has shown favorable safety profile comparable to that in the Placebo group.
Conclusion
The results of the 12-week period in the BCD-085-16/PLANETA-KIDS study have shown high efficacy of netakimab compared with placebo with favorable safety profile in children aged 6 years and older and adolescents with moderate-to-severe plaque psoriasis.
Zitieren
APA
Murashkin, N. N., Bakulev, A. L., Gorodnichev, P. V., Zaslavskiy, D. V., Ziganshin, O. R., Kokhan, M. M., Koshkin, S. V., Maksimova, A. A., Kovaleva, Y. S., Pak, T. E., Sidorenko, O. A., Sonin, D. B., Khalilov, B. V., Khotko, A. A., Artem’eva, A. V., Eremeeva, A. V., Zinkina, A. V., Lin’kova, Y. N., Kolosova, E. S., …, & Fokina, E. A. (2026). Efficacy and Safety of Netakimab in Children and Adolescents with Moderate-to-Severe Plaque Psoriasis: Results of the Core Treatment Period (12 Weeks) of the Randomized Placebo-Controlled Phase III Clinical Trial BCD-085-16/PLANETA-KIDS. Current Pediatrics, 25(3), 173-188. https://doi.org/10.15690/vsp.v25i3.3056
Vancouver
Murashkin NN, Bakulev AL, Gorodnichev PV, Zaslavskiy DV, Ziganshin OR, Kokhan MM, et al. Efficacy and Safety of Netakimab in Children and Adolescents with Moderate-to-Severe Plaque Psoriasis: Results of the Core Treatment Period (12 Weeks) of the Randomized Placebo-Controlled Phase III Clinical Trial BCD-085-16/PLANETA-KIDS. Current Pediatrics. 2026;25(3):173-188. doi:10.15690/vsp.v25i3.3056
BibTeX
@article{Murashkin2026,
author = {Murashkin, Nikolay N. and Bakulev, Andrey L. and Gorodnichev, Pavel V. and Zaslavskiy, Denis V. and Ziganshin, Oleg R. and Kokhan, Muza M. and Koshkin, Sergey V. and Maksimova, Anna A. and Kovaleva, Yulia S. and Pak, Tatiana E. and Sidorenko, Olga A. and Sonin, Dmitriy B. and Khalilov, Bulat V. and Khotko, Alkes A. and Artem’eva, Antonina V. and Eremeeva, Anna V. and Zinkina, Arina V. and Lin’kova, Yulia N. and Kolosova, Elena S. and Lutskiy, Anton A. and Fokina, Ekaterina A.},
title = {Efficacy and Safety of Netakimab in Children and Adolescents with Moderate-to-Severe Plaque Psoriasis: Results of the Core Treatment Period (12 Weeks) of the Randomized Placebo-Controlled Phase III Clinical Trial BCD-085-16/PLANETA-KIDS},
journal = {Current Pediatrics},
year = {2026},
volume = {25},
number = {3},
pages = {173--188},
doi = {10.15690/vsp.v25i3.3056}
}
EUVIMED